Journal of Cystic Fibrosis
Volume 4, Issue 3 , Pages 193-196 , September 2005

Overrepresentation of immunostimulatory CpG motifs in Burkholderia genomes

Received 17 January 2005 ,Revised 2 February 2005 ,Accepted 23 March 2005.

References 

  1. Pilewski JM, Frizzell RA. Role of CFTR in airway disease. Physiol Rev. 1999;79:S215–S255
  2. Gilligan PH. Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev. 1991;4:35–51
  3. Bals R, Weiner DJ, Wilson JM. The innate immune system in cystic fibrosis lung disease. J Clin Invest. 1999;103:303–307
  4. Elborn JS, Shale DJ. Cystic fibrosis: 2. Lung injury in cystic fibrosis. Thorax. 1990;45:970–973
  5. Kronborg G. Lipopolysaccharide (LPS), LPS-immune complexes and cytokines as inducers of pulmonary inflammation in patients with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection. APMIS Suppl. 1995;50:1–30
  6. Berger M. Inflammatory mediators in cystic fibrosis lung disease. Allergy Asthma Proc. 2002;23:19–25
  7. Wieland CW, Siegmund B, Senaldi G, Vasil ML, Dinarello CA, Fantuzzi G. Pulmonary inflammation induced by Pseudomonas aeruginosa lipopolysaccharide, phospholipase C, and exotoxin A: role of interferon regulatory factor 1. Infect Immun. 2002;70:1352–1358
  8. Hughes JE, Stewart J, Barclay GR, Govan JR. Priming of neutrophil respiratory burst activity by lipopolysaccharide from Burkholderia cepacia. Infect Immun. 1997;65:4281–4287
  9. Shaw D, Poxton IR, Govan JR. Biological activity of Burkholderia (Pseudomonas) cepacia lipopolysaccharide. FEMS Immunol Med Microbiol. 1995;11:99–106
  10. Zughaier SM, Ryley HC, Jackson SK. Lipopolysaccharide (LPS) from Burkholderia cepacia is more active than LPS from Pseudomonas aeruginosa and Stenotrophomonas maltophilia in stimulating tumor necrosis factor alpha from human monocytes. Infect Immun. 1999;67:1505–1507
  11. Lever MS, Nelson M, Ireland PI, Stagg AJ, Beedham RJ, Hall GA, et al. Experimental aerogenic Burkholderia mallei (glanders) infection in the BALB/c mouse. J Med Microbiol. 2003 (Dec);52(Pt 12):1109–1115
  12. Friedland JS, Suputtamongkol Y, Remick DG, Chaowagul W, Strieter RM, Kunkel SL, et al. Prolonged elevation of interleukin-8 and interleukin-6 concentrations in plasma and of leukocyte interleukin-8 mRNA levels during septicemic and localized Pseudomonas pseudomallei infection. Infect Immun. 1992;60:2402–2408
  13. Tokunaga T, Yamamoto H, Shimada S, Abe H, Fukuda T, Fujisawa Y, et al. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG: I. Isolation, physicochemical characterization, and antitumor activity. J Natl Cancer Inst. 1984;72:955–962
  14. Gilkeson GS, Grudier JP, Karounos DG, Pisetsky DS. Induction of anti-double stranded DNA antibodies in normal mice by immunization with bacterial DNA. J Immunol. 1989;142:1482–1486
  15. Messina JP, Gilkeson GS, Pisetsky DS. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J Immunol. 1991;147:1759–1764
  16. Tokunaga T, Yano O, Kuramoto E, Kimura Y, Yamamoto T, Kataoka T, et al. Synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of Mycobacterium bovis BCG induce interferons and activate natural killer cells. Microbiol Immunol. 1992;36:55–66
  17. Yamamoto S, Yamamoto T, Shimada S, Kuramoto E, Yano O, Kataoka T, et al. DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol Immunol. 1992;36:983–997
  18. Kuramoto E, Watanabe N, Iwata D, Yano O, Shimada S, Tokunaga T. Changes of host cell infiltration into Meth A fibrosarcoma tumor during the course of regression induced by injections of a BCG nucleic acid fraction. Int J Immunopharmacol. 1992;14:773–782
  19. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995;374:546–549
  20. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A. 1996;93:2879–2883
  21. Schmidt U, Wagner H, Miethke T. CpG-DNA upregulates the major acute-phase proteins SAA and SAP. Cell Microbiol. 1999;1:61–67
  22. Hartmann G, Weiner GJ, Krieg AM. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci U S A. 1999;96:9305–9310
  23. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000;408:740–745
  24. Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, Akira S, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A. 2001;98:9237–9242
  25. Chuang TH, Lee J, Kline L, Mathison JC, Ulevitch RJ. Toll-like receptor 9 mediates CpG-DNA signaling. J Leukoc Biol. 2002;71:538–544
  26. Hartmann G, Krieg AM. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol. 2000;164:944–953
  27. Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto I, et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol. 2000;164:1617–1624
  28. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A. 1996;93:2879–2883
  29. Hartmann G, Krieg AM. CpG DNA and LPS induce distinct patterns of activation in human monocytes. Gene Ther. 1999;6:893–903
  30. Cardon LR, Burge C, Clayton DA, Karlin S. Pervasive CpG suppression in animal mitochondrial genomes. Proc Natl Acad Sci U S A. 1994;91:3799–3803
  31. Karlin S, Campbell AM, Mrazek J. Comparative DNA analysis across diverse genomes. Annu Rev Genet. 1998;32:185–225
  32. Karlin S, Mrazek J, Campbell AM. Compositional biases of bacterial genomes and evolutionary implications. J Bacteriol. 1997;179:3899–3913

PII: S1569-1993(05)00034-2

doi: 10.1016/j.jcf.2005.03.001

Journal of Cystic Fibrosis
Volume 4, Issue 3 , Pages 193-196 , September 2005

Article Tools

* Image Usage & Resolution